Summary: Jazz Pharmaceuticals reported record revenues exceeding $1 billion for Q2 2024, driven by strong sales of Xywav in its sleep medicine portfolio, as well as Epidiolex and Rylaze in its seizure and oncology portfolios. The company saw a 13% year-over-year increase in Xywav … [Read more...]
Philips Agrees to Pay $1 Billion to Patients Who Say They Were Injured by Breathing Machines
by Debbie Cenziper, ProPublica Michael D. Sallah, Pittsburgh Publish-Gazette and Julian Andreone, Medill Investigative LabProPublica is a Pulitzer Prize-profitable investigative newsroom. Signal up for The Massive Story e-newsletter to receive stories like this one in your … [Read more...]